13 January 2021 - Deborah Wilkes
Maxwellia has appointed a finance director, Bayer has recruited a chief transformation and talent officer, and AFT Pharmaceuticals has gained expertise in North America.
Maxwellia appoints finance director
Switch specialist Maxwellia has appointed Jack Grimshaw as finance director.
The UK-based company said Grimshaw had more than 10 years of finance experience across a range of industries including retail, pharmaceuticals and financial services. It also highlighted his skills in raising funding for businesses.
Grimshaw is a former senior financial analyst for pharmacy and healthcare at UK supermarket chain Sainsbury’s. He has also worked for Arcadia Group, Atollo CEN, Buddy Loans and Co-op.
In addition to finance, Grimshaw will be responsible for supply chain, logistics, procurement, IT, legal and human resources.
Anna Maxwell, founder and chief executive officer of Maxwellia, said Grimshaw shared the company’s vision of “widening access to medicines through pharmacy” and his experience would further support the company as it entered a “very exciting new phase of growth”.
Maxwellia is one of the companies seeking to switch the progestogen-only pill from prescription-only to pharmacy status in the UK (click here to read the News story).
Bayer recruits chief transformation officer
Bayer has recruited Elanco Animal Health’s Sarena Lin as chief transformation and talent officer with effect from 1 February 2021.
Lin will be a member of the German company’s Board of Management.
Bayer said she would be responsible for human resources, strategy and business consulting, and would “drive the accelerated transformation of Bayer”. She will also serve as labour director.
Lin is a member of the Executive Committee at Elanco Animal Health, with responsibility for transformation and technology. She has also worked for McKinsey and Cargill.
AFT gains expertise in North America
New Zealand’s AFT Pharmaceuticals said Ted Witek had joined its board as an independent non-executive director.
David Flacks, AFT’s chair, said Witek’s “in-depth understanding of North American pharmaceutical regulators and markets” would be of great value as the company moved to “expand its presence in the US and Canada”.
Canada-based Witek had “more than three decades of international clinical development and leadership experience”, said AFT.
Between 2014 and 2018, Witek was senior vice president, corporate partnerships, and chief scientific officer at US-based Innoviva. Prior to that, he spent more than two decades with Boehringer Ingelheim, mainly in the US.
AFT has just made its first foray into North America with the launch of Maxigesic in Canada by BioSyent. The combination analgesic has been launched as a non-prescription medicine under the Combogesic brand name (click here to read the News story).
Witek replaces Jim Burns who will step down at AFT’s next annual meeting in August 2021.